From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: ACRL

Search articles by EPIC code

Accrol – hopefully prior warnings here were heeded as now a further profit warning and a “strategic review”

Previously writing on “the UK's leading independent tissue converter” Accrol (ACRL) in October with the shares falling below 40p, I concluded that the group argues the latest are “short-term external challenges”, but also raw material supply chains “further tightening in recent weeks”. As such, hopefully the prior warning was heeded and the stance remains avoid. Today a further trading update and the shares... further down to 25p. So what’s the latest?...

Page 1 of 5 (41 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments